Modality
Vaccine
MOA
EZH2i
Target
PRMT5
Pathway
Hedgehog
PVSCLCOCD
Development Pipeline
Preclinical
~Sep 2020
→ ~Dec 2021
Phase 1
~Mar 2022
→ ~Jun 2023
Phase 2
Sep 2023
→ Sep 2028
Phase 2Current
NCT07194762
1,768 pts·PV
2023-09→2027-02·Not yet recruiting
NCT05831728
914 pts·PV
2025-07→2028-09·Terminated
2,682 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-02-0610mo awayPh3 Readout· PV
2028-09-012.4y awayPh3 Readout· PV
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2/3
Not yet…
P2/3
Termina…
Catalysts
Ph3 Readout
2027-02-06 · 10mo away
PV
Ph3 Readout
2028-09-01 · 2.4y away
PV
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07194762 | Phase 2/3 | PV | Not yet recr... | 1768 | eGFR |
| NCT05831728 | Phase 2/3 | PV | Terminated | 914 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 | |
| Daratuximab | BioMarin | Phase 1 | PRMT5 |